特瑞普利单抗联合含铂双药化疗治疗TP53基因突变非小细胞肺癌的疗效  

Efficacy of Toripalimab Combined with Platinum-based Doublet Chemotherapy in Non-small Cell Lung Cancer with TP53 Gene Mutation

作　　者：侯聪霞[1] 孙芳[1] 梁亚林[2] 史会影 HOU Congxia;SUN Fang;LIANG Yalin(Henan Chest Hospital,Zhengzhou,450008)

机构地区：[1]河南省胸科医院,450008 [2]河南省郑州市第七人民医院,450008

出　　处：《实用癌症杂志》2023年第4期585-588,共4页The Practical Journal of Cancer

摘　　要：目的 研究特瑞普利单抗联合含铂双药化疗治疗TP53基因突变非小细胞肺癌(NSCLC)的疗效。方法 选取64例TP53基因突变NSCLC患者,随机分为对照组与研究组,各32例。2组采用含铂双药化疗方案治疗,研究组基于此联合特瑞普利单抗治疗。比较2组疗效、T细胞亚群指标(CD3+、CD4+、CD4+/CD8+)水平、免疫球蛋白指标(IgA、IgG、IgM)水平及不良反应情况。结果 研究组有效率(78.13%)高于对照组(53.13%)(P<0.05)。治疗后2组CD3+、CD4+、CD4+/CD8+较治疗前下降,但研究组CD3+、CD4+、CD4+/CD8+高于对照组(P<0.05)。治疗后2组IgA、IgG、IgM水平较治疗前下降,但研究组IgA、IgG、IgM水平高于对照组(P<0.05)。2组治疗期间发生的胃肠道反应、肝肾功能异常及白细胞、血小板减少等情况,差异无统计学意义(P>0.05)。结论 特瑞普利单抗联合含铂双药化疗可有效改善TP53基因突变NSCLC患者病情,提高机体免疫功能,且具有一定安全性。Objective To study the efficacy of toripalimab combined with platinum-based doublet chemotherapy in non-small cell lung cancer(NSCLC)with TP53 gene mutation.Methods 64 NSCLC patients with TP53 gene mutation were enrolled,and randomly divided into 2 groups,each with 32 cases.All patients received platinum-based doublet chemotherapy,based on this,the study group received toripalimab treatment.Then comparison was conducted on clinical efficacy,T-lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),immunoglobulins(IgG,IgA,IgM)and adverse reactions.Results In the control group,complete response(CR)was achieved in 1 patient,partial response(PR)was seen in 7 patients,stable disease(SD)was obtained in 9 patients,and progressive disease(PD)was seen in 15 patients.In study group,2 patients achieved CR,12 patients obtained PR,11 patients had SD,and 7 patients suffered PD.The overall efficacy rate was 78.13%in study group,which was higher than 53.13%in the control group,with statistical difference(P<0.05).CD3+,CD4+and CD4+/CD8+values were decreased in both groups after treatment,and the values of the three T-lymphocyte subsets were notably higher in the study group than in the control group,with statistical difference(P<0.05).IgA,IgG and IgM levels were also decreased in both groups after treatment,and the three indicators of the study group were higher than those of the control group(P<0.05).Adverse reactions including gastrointestinal reactions,abnormal liver and kidney functions,leukocyte and thrombocytopenia yielded no statistical difference between the 2 groups(P>0.05).Conclusion Application of toripalimab combined with platinum-based doublet chemotherapy in NSCLC patients with TP53 gene mutation can effectively and safety can effectively improve the condition and immune function in patients.

关 键 词：TP53基因突变 非小细胞肺癌 特瑞普利单抗 含铂双药化疗 疗效 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]